Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019663 | 0.94 | FLT3 (0.40) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1020114 | 0.89 | HSP90AA1 (0.42) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1019622 | 0.89 | HSP90AA1 (0.40) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL20393894 | 0.87 | FLT3 (0.50) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1019275 | 0.86 | TSHR (0.54) | FLT3ADRB2ADRB1ADRB3LIG1 | |
| SCHEMBL20391495 | 0.84 | TDP1 (0.49) | FLT3CASP1LIG1KDM4EBLM | |
| SCHEMBL1018574 | 0.81 | CHEK1 (0.41) | KDM4EGAATSHRTDP1LMNA | |
| SCHEMBL20677873 | 0.80 | GAA (0.47) | FLT3CASP1LIG1KDM4EBLM | |
| SCHEMBL10246545 | 0.80 | THRA (0.42) | CASP1KDM4EGAATSHRTDP1 | |
| SCHEMBL29116983 | 0.80 | FLT3 (0.47) | FLT3CASP1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889552-B2 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | ONCOZEN CO.. LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-10464907-B2 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-11-05 | — | — | US | disclosed |
| US-20190031620-A1 | NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | FLT3 2313/4885CASP1 1008/4885ADRB2 378/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | FLT3 3144/4885CASP1 4444/4885ADRB2 25/4885 |
| US-10889552-B2 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | HSP90AB1, HSP90AA1, HSP90AB2P | FLT3 2577/4885CASP1 2894/4885ADRB2 3782/4885 |
| US-20190031620-A1 | NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF | HSP90AA1, HSP90AB1, HSP90AB2P | FLT3 2050/4885CASP1 2360/4885ADRB2 4521/4885 |
| US-10464907-B2 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | HSP90AA1, HSP90AB1, HSP90AB2P | FLT3 2065/4885CASP1 2359/4885ADRB2 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.